Abstract 5640
Background
Lymphocyte-activation gene 3 (LAG-3) is a negative regulator of immune response implicated in T cell exhaustion and tumor immune escape. Available data demonstrate that tumor-derived T cells frequently co-express the PD-1 and LAG-3 co-inhibitory receptors and that dual blockade of the LAG-3 and PD-1 pathways results in more potent reactivation of T-cell function and anti-tumor immune response than blockade of the individual pathway. BI 754091 and BI 754111 are monoclonal IgG4Pro antibodies (mAbs) against PD-1 and LAG-3, respectively. In this Phase I study, we investigate the safety, tolerability, PK, and preliminary efficacy of the combination of these 2 mAbs.
Trial design
This 2-part, open-labeled, non-randomized ongoing study consists of dose escalation in pts with advanced solid tumors followed by expansion cohorts in pts with NSCLC, microsatellite stable (MSS) mCRC, or any PD-1/PD-L1 pretreated solid tumor with high tumor mutational burden (TMB-H) and/or high microsatellite instability and/or DNA mismatch repair deficiency (MSI-H/MMRd). Dose escalation in pts with solid tumors started at 4mg q3w BI 754111 and was guided by Bayesian Logistic Regression Method. All dose levels of BI 754111 were co-administered with 240 mg q3w BI 754091 (the BI 754091 RPIID selected from 1381.1 phase I [Johnson, et al. ASCO-SITC 2017 abstract 212]). Enrollment in the solid tumor dose escalation portion is nearly complete. The expansion phase will use a combination dose selected from the solid tumor dose escalation. Primary endpoints in the dose escalation are the number of pts with dose-limiting toxicities and the combination MTD. The primary endpoint of the dose expansion portion is the objective response rate.
Clinical trial identification
NCT03156114.
Legal entity responsible for the study
Boehringer Ingelheim Pharmaceuticals, Inc.
Funding
Boehringer Ingelheim Pharmaceuticals, Inc.
Editorial Acknowledgement
Disclosure
M. Elgadi: Employee: Boehringer Ingelheim (Canada) Ltd./Ltee. M. Ge, C. Duffy: Employee: Boehringer Ingelheim Pharmaceuticals, Inc. R. Graeser: Employee: Boehringer Ingelheim Pharma GmbH & Co. KG. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract